Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Do you recommend ADT for a high risk prostate cancer patient who had SBRT?
If so, how long?
Answer from: Radiation Oncologist at Community Practice
SBRT doesn’t mitigate benefit of ADT and the type and duration have to be the same as with EBRT or EBRT plus brachytherapy.
Comments
Radiation Oncologist at Genesis Healthcare Partners- San Diego
Since ADT has no benefit in high risk prostate ca ...
Radiation Oncologist at Varian Medical Systems/Allegheny health network
Ma et al., PMID 35934601 This article highlight...
6993
6998
Sign In
or
Register
to read more
Answer from: Radiation Oncologist at Academic Institution
I would not treat a high risk patient with SBRT.
Sign In
or
Register
to read more
14207
14233
Related Questions
Are there any scenarios in which you would offer SBRT as your preferred treatment approach for appropriate candidates with intermediate risk prostate cancer?
Would you ever re-irradiate the groin/inguinal region?
Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?
Do you recommend placement of a rectal spacer when delivering radiotherapy to the prostate in patients with oligometastatic prostate cancer?
Given results of the RADICALS trials, is LT-ADT standard of care for salvage prostate RT?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
How do you manage bladder spasms during pelvic radiotherapy?
How would you treat a young man with a history of stage IA testicular pure seminoma s/p radical orchiectomy who has a solitary left inguinal lymph node recurrence and normal tumor markers?
In a patient with a synchronous prostate cancer and non-invasive urothelial carcinoma limited to the prostatic urethra is complete TUR and definitive prostate dose to standard prostate fields adequate treatment?
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Since ADT has no benefit in high risk prostate ca ...
Ma et al., PMID 35934601 This article highlight...